Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00016237
Recruitment Status : Completed
First Posted : January 7, 2004
Last Update Posted : October 23, 2013
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Information provided by:
EMD Serono

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : No date given
  Study Completion Date : No date given